Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Wakamoto Pharmaceutical CoTSE:4512 63 Gross Margin % is 49.48% as of Mar. 2026, which is 3% below its 10-year median of 51.21. GuruFocus rates TSE:4512 with a GF Score™ of 63/100 and a GF Value™ of 円319.14 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 943 Drug Manufacturers companies, Wakamoto Pharmaceutical Co ranks worse than 51.75% on this metric.
Wakamoto Pharmaceutical Co (TSE:4512) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Wakamoto Pharmaceutical Co had a gross margin of 49.48% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Wakamoto Pharmaceutical Co Gross Margin % Related Terms
Wakamoto Pharmaceutical Co Gross Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Wakamoto Pharmaceutical Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Wakamoto Pharmaceutical Co Gross Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Wakamoto Pharmaceutical Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Wakamoto Pharmaceutical Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Wakamoto Pharmaceutical Co (TSE:4512) has a Gross Margin % of 49.48% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Wakamoto Pharmaceutical Co and its competitors. This is near median its historical median of 51.21. Over the past decade, Wakamoto Pharmaceutical Co's Gross Margin % has ranged from 46.50 to 56.96. According to the industry distribution chart, Wakamoto Pharmaceutical Co ranks #488 out of 943 companies in the Drug Manufacturers industry, placing it in the top 51.7%.
Is Wakamoto Pharmaceutical Co's Gross Margin % too high?
Wakamoto Pharmaceutical Co's current Gross Margin % of 49.48% is near median its 10-year median of 51.21. Over the past 10 years, this metric has ranged from a low of 46.50 to a high of 56.96. The Drug Manufacturers industry median Gross Margin % is 48.54. Wakamoto Pharmaceutical Co's value of 49.48% is 1.9% above this industry median. Based on the distribution chart, Wakamoto Pharmaceutical Co ranks #488 out of 943 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Wakamoto Pharmaceutical Co has a GF Score™ of 63/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Wakamoto Pharmaceutical Co's Gross Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Wakamoto Pharmaceutical Co ranks #488 out of 943 companies for Gross Margin %. This places Wakamoto Pharmaceutical Co in the lower half of its industry. The industry median Gross Margin % is 48.54. Wakamoto Pharmaceutical Co's value of 49.48% is 1.9% above this benchmark. Historically, Wakamoto Pharmaceutical Co's own Gross Margin % has ranged from 46.50 to 56.96 over the past decade. While the company's 10-year median is 51.21 vs. the industry median of 48.54, Wakamoto Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Drug Manufacturers company?
The median Gross Margin % among Drug Manufacturers companies is 48.54, based on 943 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Wakamoto Pharmaceutical Co's current Gross Margin % of 49.48% is 1.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Wakamoto Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median Gross Margin % is 48.54 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Wakamoto Pharmaceutical Co's current Gross Margin % is 49.48%, which is near median its own 10-year median of 51.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Wakamoto Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co (TSE:4512) is currently considered Modestly Undervalued. The stock's GF Value™ is 円319.14, compared to a current price of 円278.00 — trading 12.9% below its estimated fair value. The current Gross Margin % is 49.48%, which is near median its 10-year median of 51.21 and 1.9% above the Drug Manufacturers industry median of 48.54. Wakamoto Pharmaceutical Co's overall GF Score™ is 63/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Wakamoto Pharmaceutical Co (TSE:4512), the current Gross Margin % is 49.48% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Wakamoto Pharmaceutical Co (TSE:4512) Overvalued in 2026?
Based on GuruFocus' analysis, Wakamoto Pharmaceutical Co stock appears to be undervalued.
The current stock price of 円278.00 is trading 12.9% below its estimated GF Value™ of 円319.14.
GuruFocus considers Wakamoto Pharmaceutical Co to be Modestly Undervalued.
Key valuation signals for TSE:4512:
Gross Margin %: 49.48% (near median its 10-year median of 51.21)
GF Value™: 円319.14 vs. price of 円278.00 (12.9% below fair value)
Industry Position: 1.9% above the Drug Manufacturers median (#488 of 943)
No single metric tells the full story. See the TSE:4512 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Wakamoto Pharmaceutical Co Ltd is the pharmaceutical company based in Japan. It is engaged in the research and development, production and sale of ethical drugs and non-prescription drugs. The company specializes in therapeutic and diagnostic agents for ophthalmic disorders. It offers Strong Wakamoto, a gastrointestinal drug for digestion, the intestinal function controlling, and nutritional supply.
63GF Score
Get the complete analysis for TSE:4512
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4512 has been successfully added to your 
